Dario M.

Investigator advances therapeutic options for glomerular diseases, targeting proteinuria reduction.

• Idiopathic IgA Nephropathy
• Early corticosteroid therapy after kidney biopsy
• SGLT2 inhibitor combined with RAS blockers
• Corticosteroid‑based regimens versus standard care

Efforts aim to balance efficacy with safety by minimizing steroid‑related adverse effects.

Investigator explores acute coronary syndromes and microvascular protection to lower cardiac events.

• ST‑Elevation Myocardial Infarction with multivessel disease
• Late INa current inhibition for microvascular dysfunction
• Cardiovascular safety of novel agents in overweight patients
• Major adverse cardiovascular events (MACE) outcomes

Studies assess both procedural and pharmacologic strategies to preserve coronary function.

Investigator addresses glycemic control and weight management through emerging pharmacotherapies.

• Type 2 Diabetes Mellitus with individualized HbA1c targets
• Obesity and overweight interventions
• Semaglutide as adjunct to reduced‑dose insulin
• Tirzepatide for morbidity and mortality reduction
• SGLT2 inhibitors to stabilize coronary atherosclerosis post‑MI

Research emphasizes cardiovascular risk mitigation alongside metabolic improvement.

Investigator contributes to therapeutic evaluation for viral respiratory illnesses, focusing on high‑risk populations.

• SARS‑CoV‑2 infection in hospitalized patients
• Baricitinib added to standard of care for immunocompromised hosts
• Outcome measures of disease progression and mortality
• Adaptive platform trial designs for emerging infections

Efforts target reduction of severe outcomes through targeted antiviral and anti‑inflammatory agents.